Targeted therapeutic drug for lung cancer cells and preparation method of targeted therapeutic drug
By designing EG20-XI N drugs, the problems of low efficacy and drug resistance in EGFR 20i ns mutant lung cancer have been solved, enabling precise targeted therapy of EGFR 20i ns mutant lung cancer cells, improving treatment efficacy and enhancing drug membrane penetration and stability, and supporting pharmacokinetic studies.
Patent Information
- Application Number
- CN202411139035.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-26
AI Technical Summary
Current treatments for EGFR exon 20 insertion mutation-positive lung cancer are not ideal, with issues of drug resistance and safety. Furthermore, the efficacy and tolerability of novel targeted therapies require further evaluation.
A lung cancer cell-targeted therapy drug, EG20-XI N, was designed by linking a fluoropyridine group and a long-chain alkane group substituted with a trifluoromethylsulfonyl group to the benzimidazole core structure to enhance its specific binding ability to the EGFR 20i ns mutation site. The drug was prepared by high-pressure amidation reaction and isotope labeling.
This approach enables precise targeted therapy of EGFR 20i ns mutant lung cancer cells, improving treatment efficacy, reducing side effects, enhancing drug membrane penetration and stability, and supporting pharmacokinetic studies.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention relates to the field of tunnel engineering, and in particular to a lung cancer cell targeted therapeutic drug and a preparation method thereof. Background Art
[0002] In the treatment of lung cancer, especially non-small cell lung cancer (NSCLC), molecular targeted therapy has become an important treatment method. Among them, epidermal growth factor receptor (EGFR) gene mutation is one of the most critical driver genes in NSCLC, and drug development targeting this target has made significant progress. However, among the various types of EGFR mutations, the treatment of exon 20 insertion mutation (EGFR 20i ns) still faces great challenges.
[0003] At present, targeted drugs for EGFR mutations are mainly divided into several generations of tyrosine kinase inhibitors (TKIs). First-generation TKIs such as gefitinib, erlotinib and icotinib, as well as second-generation TKIs such as afatinib and dacomitinib, have shown good efficacy in treating common EGFR mutations (such as exon 19 deletions and exon 21 point mutations). However, these drugs are not ideal for the treatment of patients with EGFR 20i ns, with low objective response rates (ORR) and overall survival (OS), and are prone to drug resistance.
[0004] In recent years, with the in-depth study of the mechanism of EGFR 20i ns, some new targeted drugs have gradually entered the clinical trial stage. For example, osimertinib, as a third-generation TKIs, has shown certain anti-tumor activity in some patients with EGFR 20i ns, but its efficacy is still controversial and needs further verification in large-sample clinical trials. In addition, new drugs such as Mobocertinib (TAK 788), Poziotinib, and Ami vantamab (JNJ 6372) also show therapeutic potential for patients with EGFR 20i ns, but their efficacy, safety, and patient tolerance still need further evaluation.
[0005] It is worth noting that although these new drugs provide new treatment options for patients with EGFR 20i ns, their efficacy is not completely satisfactory and has many limitations. Therefore, the development of a new targeted drug with high selectivity and efficacy for EGFR 20i ns remains a hot topic and difficulty in current clinical research. Summary of the invention
[0006] The purpose of the present invention is to provide a lung cancer cell targeted therapeutic drug and a preparation method thereof, aiming to solve the problems of low efficacy, drug resistance, safety and tolerability, and brain penetration activity of EGFR 20i ns mutation mentioned in the prior art.
[0007] To achieve the above object, the present invention provides the following technical solutions:
[0008] A lung cancer cell targeted therapeutic drug, which is a drug compound EG20-XI N,
[0009] A benzimidazole core structure; its N-1 position is protected by a chloroacetyl group, serving as the active site for subsequent reactions;
[0010] at least one fluoropyridine group connected to the benzimidazole core via an amide bond;
[0011] At least one trifluoromethylsulfonyl-substituted long-chain alkane group connected to the benzimidazole core; connected to another substitutable position of the benzimidazole core via an ester bond or an amide bond to enhance the membrane permeability and stability of the drug;
[0012] The chemical structure is as follows,
[0013]
[0014] Wherein, R1 is a fluoropyridine group, R2 is a trifluoromethylsulfonyl group, and [benzene ring] and [imidazole ring] represent the skeleton structure of benzimidazole.
[0015] In a preferred technical solution, the fluoropyridine group is a fluoropyridin-3-yl group, which is connected to the N-3 position of the benzimidazole core via an amide bond, thereby providing specific binding ability to the EGFR 20i ns mutation site.
[0016] A preferred technical solution, a lung cancer cell targeted therapeutic drug, further comprises at least one isotope-labeled atom for drug metabolomics research or biodistribution imaging, wherein the isotope includes but is not limited to deuterium, carbon-14 or fluorine-18.
[0017] A method for preparing a lung cancer cell targeted therapeutic drug comprises the following steps:
[0018] Step 1: preparing intermediate A, which is an N-chloroacetyl derivative of benzimidazole;
[0019] Step 2: preparing a key raw material B, which comprises a fluoropyridine group and a long-chain alkane group substituted with a trifluoromethylsulfonyl group, and is obtained by multi-step organic synthesis;
[0020] Step 3: Under high pressure conditions of 10-50 MPa, the intermediate A and the key raw material B are subjected to amidation reaction under alkaline conditions to obtain a crude product of EG20-XI N;
[0021] Step 4: Purify the crude product by column chromatography and recrystallization to obtain high-purity EG20-XI N.
[0022] In the preferred technical solution, the specific operation of step 1 is: in an anhydrous solvent, benzimidazole and chloroacetyl chloride are reacted in the presence of an alkaline catalyst to obtain intermediate A, which is used after post-treatment and purification.
[0023] The specific operation of step 2 is as follows: including a Grignard reaction step, converting fluoropyridine into the corresponding Grignard reagent, and then reacting with an acyl chloride to obtain an amide acid, which is further converted into the desired key raw material B and used after purification.
[0024] The targeted therapeutic drug "EG20-XI N" is used in the preparation of a pharmaceutical composition for treating or preventing EGFR 20 exon insertion mutation-type lung cancer.
[0025] A composition comprising a lung cancer cell targeted therapeutic drug is a pharmaceutically acceptable carrier or excipient, which further comprises one or more excipients for enhancing the solubility, stability or targeting of the drug, wherein the excipient is one or more of cyclodextrin inclusion complexes, liposomes or nanoparticles.
[0026] A composition comprising a lung cancer cell targeted therapeutic drug is used for treating or preventing EGFR exon 20 insertion mutation type lung cancer.
[0027] Compared with the prior art, the present invention has the following beneficial effects:
[0028] Highly specific targeting:
[0029] EG20-X IN drug compound has a unique chemical structure design, especially the fluoropyridine group is connected to the N-3 position of the benzimidazole core through an amide bond, which provides specific binding ability to the EGFR 20 exon insertion mutation (EGFR 20i ns) site. This specific binding enables EG20-X IN to accurately target and inhibit EGFR 20i ns mutant lung cancer cells, while having no significant inhibitory effect on wild-type cell lines, thereby improving the therapeutic effect and reducing side effects.
[0030] Enhanced membrane penetration and stability:
[0031] The long-chain alkane group substituted with trifluoromethylsulfonyl introduced into the drug molecule is connected to another substitutable position of the benzimidazole core through an ester bond or an amide bond, which not only enhances the membrane permeability of the drug, but also improves its stability. This design helps the drug molecule to better penetrate the cell membrane, reach the target location, and maintain its activity, thereby improving the therapeutic efficiency.
[0032] Efficient drug preparation method:
[0033] The use of microwave-assisted or ultrasound-promoted chloroacetylation and amidation under high pressure significantly improved the yield and purity of intermediate A and key raw material B, and also promoted the synthesis of EG20-X IN. This efficient and controllable preparation method helps to reduce production costs, improve product quality, and provide strong support for the large-scale production of drugs.
[0034] Pharmacokinetics and biodistribution studies:
[0035] Provided are EG20-XI N drug variants containing isotope-labeled atoms, including but not limited to deuterium, carbon-14 or fluorine-18. These isotope-labeled drugs can be used for pharmacokinetic studies and biodistribution imaging, which helps to gain a deeper understanding of the absorption, distribution, metabolism and excretion of drugs in the body, and provide important references for the clinical application of drugs.
[0036] Diversity and enhanced effects of drug compositions:
[0037] Provided are pharmaceutical compositions comprising EG20-XI N, which may comprise a pharmaceutically acceptable carrier or excipient, and one or more adjuvants that enhance drug solubility, stability or targeting. These adjuvants, such as cyclodextrin inclusion compounds, liposomes or nanoparticles, may further improve the bioavailability and therapeutic effect of the drug, and meet the therapeutic needs of different patients. DETAILED DESCRIPTION
[0038] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0039] In order to facilitate the understanding of the present invention, the present invention will be described more fully below. Several embodiments of the present invention are given. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the disclosure of the present invention more thorough and comprehensive.
[0040] A lung cancer cell targeted therapeutic drug, which is a drug compound EG20-XI N,
[0041] A benzimidazole core structure; its N-1 position is protected by a chloroacetyl group, serving as the active site for subsequent reactions;
[0042] at least one fluoropyridine group connected to the benzimidazole core via an amide bond;
[0043] At least one trifluoromethylsulfonyl-substituted long-chain alkane group connected to the benzimidazole core; connected to another substitutable position of the benzimidazole core via an ester bond or an amide bond to enhance the membrane permeability and stability of the drug;
[0044] The chemical structure is as follows,
[0045]
[0046] Wherein, R1 is a fluoropyridine group, R2 is a trifluoromethylsulfonyl group, and [benzene ring] and [imidazole ring] represent the skeleton structure of benzimidazole.
[0047] The fluoropyridine group is a fluoropyridin-3-yl group, which is connected to the N-3 position of the benzimidazole core via an amide bond, providing specific binding ability to the EGFR 20i ns mutation site.
[0048] A lung cancer cell targeted therapeutic drug further comprises at least one isotope-labeled atom for drug metabolism kinetics research or biodistribution imaging, wherein the isotope includes but is not limited to deuterium, carbon-14 or fluorine-18.
[0049] A method for preparing a lung cancer cell targeted therapeutic drug comprises the following steps:
[0050] Step 1: preparing intermediate A, which is an N-chloroacetyl derivative of benzimidazole; using microwave-assisted or ultrasonic-promoted chloroacetylation reaction to improve the yield and purity of intermediate A (N-chloroacetyl derivative of benzimidazole); the reaction formula is as follows:
[0051] [Benzimidazole] + C l CH2COCl → [Benzimidazole-N-chloroacetyl] + HCl
[0052] In an anhydrous solvent (such as dichloromethane), benzimidazole is reacted with chloroacetyl chloride under alkaline conditions (such as in the presence of triethylamine) to obtain chloroacetylbenzimidazole (intermediate A).
[0053] Step 2: Prepare the key raw material B, which contains a fluoropyridine group and a long-chain alkane group substituted with a trifluoromethylsulfonyl group, and is obtained by multi-step organic synthesis; the reaction formula is as follows:
[0054] [Fluoropyridine] → [Fluoropyridine Grignard reagent] → [Fluoropyridine amide acid]
[0055] First, the fluoropyridine is converted into the corresponding Grignard reagent through the Grignard reaction, and then reacted with the acyl chloride to obtain the amide acid, which is purified to obtain the key raw material B (the specific reaction conditions need to be optimized in detail).
[0056] Step 3: Under high pressure conditions of 10-50 MPa, the intermediate A and the key raw material B are subjected to an amidation reaction under alkaline conditions to obtain a crude product of EG20-XI N; a high boiling point solvent and a special catalyst (such as a chiral catalyst) are used to promote the amidation reaction of the key raw material B (a complex amide acid containing fluoropyridine and trifluoromethylsulfonyl) and the intermediate A to obtain EG20-XI N with high stereoselectivity; the reaction formula is as follows:
[0057] [Intermediate A] + [Key raw material B] → EG20-XI N + by-product
[0058] Step 4: Purify the crude product by column chromatography, recrystallization and other methods to obtain high-purity EG20-XI N.
[0059] The specific operation of step 1 is: in an anhydrous solvent, benzimidazole is reacted with chloroacetyl chloride in the presence of a basic catalyst to obtain intermediate A, which is used after post-treatment and purification.
[0060] The specific operation of step 2 is as follows: including a Grignard reaction step, converting fluoropyridine into the corresponding Grignard reagent, and then reacting with an acyl chloride to obtain an amide acid, which is further converted into the desired key raw material B and used after purification.
[0061] The targeted therapeutic drug "EG20-XI N" is used in the preparation of a pharmaceutical composition for treating or preventing EGFR 20 exon insertion mutation-type lung cancer.
[0062] A composition comprising a lung cancer cell targeted therapeutic drug is a pharmaceutically acceptable carrier or excipient, which further comprises one or more excipients for enhancing the solubility, stability or targeting of the drug, wherein the excipient is one or more of cyclodextrin inclusion complexes, liposomes or nanoparticles.
[0063] A composition comprising a lung cancer cell targeted therapeutic drug is used for treating or preventing EGFR exon 20 insertion mutation type lung cancer.
[0064] The following is the specific preparation process of the embodiment and the corresponding parameter table:
[0065] Preparation of Intermediate A
[0066]
[0067] Preparation table of raw material B
[0068]
[0069] Synthesis and characterization of EG20-XI N
[0070]
[0071]
[0072] In vitro activity test table
[0073]
[0074]
[0075] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A lung cancer cell targeted therapeutic drug, characterized in that: It is a drug compound EG20-XIN, a benzimidazole core structure; at least one fluoropyridine group connected to the benzimidazole core via an amide bond; at least one trifluoromethylsulfonyl-substituted long chain alkane group attached to the benzimidazole core; The chemical structure is as follows, Wherein, R1 is a fluoropyridine group, R2 is a trifluoromethylsulfonyl group, and [benzene ring] and [imidazole ring] represent the skeleton structure of benzimidazole.
2. A lung cancer cell targeted therapeutic drug according to claim 1, characterized in that: The fluoropyridine group is fluoropyridin-3-yl.
3. The lung cancer cell targeted therapeutic drug according to claim 1, characterized in that: Also included is at least one isotopically labeled atom for use in pharmacokinetic studies or biodistribution imaging, including but not limited to deuterium, carbon-14 or fluorine-18.
4. The method for preparing a lung cancer cell targeted therapeutic drug according to claim 1, characterized in that: The following steps are included: Step 1: preparing intermediate A, which is an N-chloroacetyl derivative of benzimidazole; Step 2: preparing a key raw material B, which comprises a fluoropyridine group and a long-chain alkane group substituted with a trifluoromethylsulfonyl group, and is obtained by multi-step organic synthesis; Step 3: Under high pressure conditions of 10-50 MPa, the intermediate A and the key raw material B are subjected to amidation reaction under alkaline conditions to obtain a crude product of EG20-XIN; Step 4: Purify the crude product by column chromatography and recrystallization to obtain high-purity EG20-XIN.
5. The method for preparing a lung cancer cell targeted therapeutic drug according to claim 4, characterized in that: The specific operation of step 1 is: in an anhydrous solvent, benzimidazole is reacted with chloroacetyl chloride in the presence of a basic catalyst to obtain intermediate A, which is used after post-treatment and purification.
6. The method for preparing a lung cancer cell targeted therapeutic drug according to claim 4, characterized in that: The specific operation of step 2 is as follows: including a Grignard reaction step, converting fluoropyridine into the corresponding Grignard reagent, and then reacting with an acyl chloride to obtain an amide acid, which is further converted into the desired key raw material B and used after purification.
7. The method for preparing a lung cancer cell targeted therapeutic drug according to claim 4, characterized in that: The targeted therapeutic drug "EG20-XIN" is used in the preparation of a pharmaceutical composition for treating or preventing EGFR 20 exon insertion mutation-type lung cancer.
8. A composition comprising the lung cancer cell targeted therapeutic drug according to claim 1, characterized in that: It is a pharmaceutically acceptable carrier or excipient, which also contains one or more auxiliary materials for enhancing the solubility, stability or targeting of the drug, and the auxiliary materials are one or more of cyclodextrin inclusion compounds, liposomes or nanoparticles.
9. The composition according to claim 8, characterized in that: Used to treat or prevent EGFR exon 20 insertion mutation-type lung cancer.
Citation Information
Cited By
Method for co-producing quinoline acyl chloride and 2-substituted acetyl chloride from trichloromethyl quinoline and 2-substituted acetic acid
CN120383561A
